Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Read Article
News
2024
2023
Archive
Search news articles
November 10, 2021
Nouscom to Present Interim Data From Phase 1 Trial Evaluating NOUS-209, an “Off-The-Shelf” Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors
November 10, 2021
Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List
November 10, 2021
Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease
November 8, 2021
Akouos Appoints Stacy Price as Chief Technical Officer
November 4, 2021
NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study
November 2, 2021
Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV
October 29, 2021
Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering
October 28, 2021
Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies
October 27, 2021
Pear Therapeutics and Thimble Point Aquisition Corp. Announce Effectiveness of S-4 Registration Statement and Set November 23, 2021 for Thimble Point Special Stockholder Meeting to Vote on Proposed Business Combination
October 21, 2021
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
« Previous Page
1
…
31
32
33
34
35
…
118
Next Page »